Summary
Redhill Pharma’s latest secondary delivered an awful gut-punch to shareholders; there are lessons to be learned.
Lesson 1: it always takes more time to develop a great pharma pipeline into saleable, much less profitable, products.
Lesson 2: a corollary to lesson 1 is that it always takes more money to develop them.
Lesson 3: busy pipelines can signal potential cost pressures.
Observation: Redhill’s side business is still a work in progress.
Redhill Biopharma (RDHL) is a promising late clinical stage pharmaceutical company. Its recent distressing price action contains lessons that can help inform investment in many young pharma companies which have yet to realize sustainable product revenues. This posting will set out the lessons I have drawn while exploring Redhill’s urgent efforts to right its ship.
